Skip to main content Skip to section navigation Skip to footer
Mineralys Therapeutics, Inc.
  • About
  • Team
  • Investor Relations
  • Publications
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • SEC Filings
    • All SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Mar 15, 2023 4:01 pm EDT

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 04, 2023 4:30 pm EST

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Mar 01, 2023 4:05 pm EST

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

Feb 20, 2023 8:00 am EST

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

Feb 14, 2023 4:01 pm EST

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Feb 09, 2023 6:34 pm EST

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

Nov 16, 2022 8:30 am EST

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

Jun 08, 2022 8:00 am EDT

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

Mar 15, 2022 8:00 am EDT

Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer and Chief Business Officer

Apr 06, 2021 7:00 am EDT

Mineralys Therapeutics Closes $40 Million Series A Funding

rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 Mineralys Therapeutics, LLC
  • Terms & Conditions
  • Privacy Policy
  • Twitter
  • Linkedin